Announcement • Jun 30
Fujian Aonong Biological Technology Group Incorporation Limited to Report First Half, 2026 Results on Aug 31, 2026 Fujian Aonong Biological Technology Group Incorporation Limited announced that they will report first half, 2026 results on Aug 31, 2026 Announcement • May 27
Fujian Aonong Biological Technology Group Incorporation Limited, Annual General Meeting, Jun 16, 2026 Fujian Aonong Biological Technology Group Incorporation Limited, Annual General Meeting, Jun 16, 2026, at 14:00 China Standard Time. Location: Zhangzhou Science and Technology Park, Intersection of Xingting Road and Baolian Road, Shiting Town, Xiangcheng District, Zhangzhou, Fujian China Reported Earnings • Apr 24
Full year 2025 earnings released: EPS: CN¥0.03 (vs CN¥0.67 in FY 2024) Full year 2025 results: EPS: CN¥0.03 (down from CN¥0.67 in FY 2024). Revenue: CN¥8.47b (down 3.3% from FY 2024). Net income: CN¥77.6m (down 87% from FY 2024). Profit margin: 0.9% (down from 6.6% in FY 2024). Over the last 3 years on average, earnings per share has increased by 52% per year but the company’s share price has fallen by 31% per year, which means it is significantly lagging earnings. Announcement • Mar 30
Fujian Aonong Biological Technology Group Incorporation Limited to Report Q1, 2026 Results on Apr 28, 2026 Fujian Aonong Biological Technology Group Incorporation Limited announced that they will report Q1, 2026 results on Apr 28, 2026 Announcement • Dec 26
Fujian Aonong Biological Technology Group Incorporation Limited to Report Fiscal Year 2025 Results on Apr 23, 2026 Fujian Aonong Biological Technology Group Incorporation Limited announced that they will report fiscal year 2025 results on Apr 23, 2026 New Risk • Nov 13
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Chinese stocks, typically moving 9.4% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (currently running at an operating cash loss). Share price has been highly volatile over the past 3 months (9.4% average weekly change). High level of non-cash earnings (49% accrual ratio). Shareholders have been substantially diluted in the past year (199% increase in shares outstanding). Board Change • Nov 08
Less than half of directors are independent There are 6 new directors who have joined the board in the last 3 years. Of these new board members, 1 was an independent director. The company's board is composed of: 3 independent directors. 5 non-independent directors. Independent Director Daojin Yu was the last independent director to join the board, commencing their role in 2025. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Reported Earnings • Oct 28
Third quarter 2025 earnings released: EPS: CN¥0.02 (vs CN¥0.32 loss in 3Q 2024) Third quarter 2025 results: EPS: CN¥0.02 (up from CN¥0.32 loss in 3Q 2024). Revenue: CN¥2.38b (up 4.8% from 3Q 2024). Net income: CN¥53.1m (up CN¥332.1m from 3Q 2024). Profit margin: 2.2% (up from net loss in 3Q 2024). Over the last 3 years on average, earnings per share has increased by 42% per year but the company’s share price has fallen by 28% per year, which means it is significantly lagging earnings. Announcement • Sep 30
Fujian Aonong Biological Technology Group Incorporation Limited to Report Q3, 2025 Results on Oct 28, 2025 Fujian Aonong Biological Technology Group Incorporation Limited announced that they will report Q3, 2025 results on Oct 28, 2025 New Risk • Sep 17
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 6.9% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (currently running at an operating cash loss). High level of non-cash earnings (48% accrual ratio). Shareholders have been substantially diluted in the past year (199% increase in shares outstanding). Minor Risk Share price has been volatile over the past 3 months (6.9% average weekly change). Valuation Update With 7 Day Price Move • Sep 15
Investor sentiment improves as stock rises 17% After last week's 17% share price gain to CN¥6.04, the stock trades at a trailing P/E ratio of 10.6x. Average trailing P/E is 31x in the Food industry in China. Total loss to shareholders of 65% over the past three years. Valuation Update With 7 Day Price Move • Sep 01
Investor sentiment improves as stock rises 22% After last week's 22% share price gain to CN¥4.60, the stock trades at a trailing P/E ratio of 8.1x. Average trailing P/E is 30x in the Food industry in China. Total loss to shareholders of 77% over the past three years. New Risk • Aug 28
New major risk - Financial position The company's debt is not well covered by operating cash flow. Currently running at an operating cash loss. This is considered a major risk. If the company's operating cash flows are too small relative to the size of their debt, it increases their balance sheet risk. The company has less cash from operations to cover its expenses from servicing large debt and it increases the risk of liquidity issues. It also extends the time it would take for the company to pay back the debt in full, meaning it may not be able to easily pay it all off in a distress scenario. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (currently running at an operating cash loss). High level of non-cash earnings (48% accrual ratio). Shareholders have been substantially diluted in the past year (199% increase in shares outstanding). Reported Earnings • Aug 27
Second quarter 2025 earnings released: EPS: CN¥0.059 (vs CN¥0.28 loss in 2Q 2024) Second quarter 2025 results: EPS: CN¥0.059 (up from CN¥0.28 loss in 2Q 2024). Revenue: CN¥2.17b (down 3.3% from 2Q 2024). Net income: CN¥142.5m (up CN¥390.5m from 2Q 2024). Profit margin: 6.6% (up from net loss in 2Q 2024). Over the last 3 years on average, earnings per share has increased by 30% per year but the company’s share price has fallen by 39% per year, which means it is significantly lagging earnings. Announcement • Jun 30
Fujian Aonong Biological Technology Group Incorporation Limited to Report First Half, 2025 Results on Aug 26, 2025 Fujian Aonong Biological Technology Group Incorporation Limited announced that they will report first half, 2025 results on Aug 26, 2025 Announcement • May 30
Fujian Aonong Biological Technology Group Incorporation Limited, Annual General Meeting, Jun 24, 2025 Fujian Aonong Biological Technology Group Incorporation Limited, Annual General Meeting, Jun 24, 2025, at 14:00 China Standard Time. New Risk • May 14
New major risk - Financial position The company's debt is not well covered by operating cash flow. Currently running at an operating cash loss. This is considered a major risk. If the company's operating cash flows are too small relative to the size of their debt, it increases their balance sheet risk. The company has less cash from operations to cover its expenses from servicing large debt and it increases the risk of liquidity issues. It also extends the time it would take for the company to pay back the debt in full, meaning it may not be able to easily pay it all off in a distress scenario. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (currently running at an operating cash loss). Shareholders have been substantially diluted in the past year (199% increase in shares outstanding). New Risk • May 06
New major risk - Earnings quality The company has a high level of non-cash earnings. Accrual ratio: 33% This is considered a major risk. Non-cash earnings can arise from many different things. However, if a company consistently has a high level of non-cash earnings, it may be a sign that they are recognizing revenue from customers before the full value of the sales are received as cash or they are not depreciating the value of their assets appropriately. These are practices that inflate earnings, while not providing a similar increase to cash flows. Companies in some select industries naturally have a high level of non-cash earnings and it is not a major concern. However, in the worst case scenario it can be an early sign of performance manipulation by management. Currently, the following risks have been identified for the company: Major Risks High level of non-cash earnings (33% accrual ratio). Shareholders have been substantially diluted in the past year (199% increase in shares outstanding). Reported Earnings • Apr 15
Full year 2024 earnings released: EPS: CN¥0.67 (vs CN¥4.21 loss in FY 2023) Full year 2024 results: EPS: CN¥0.67 (up from CN¥4.21 loss in FY 2023). Revenue: CN¥8.76b (down 55% from FY 2023). Net income: CN¥579.3m (up CN¥4.23b from FY 2023). Profit margin: 6.6% (up from net loss in FY 2023). The move to profitability was driven by lower expenses. Over the last 3 years on average, earnings per share has fallen by 1% per year but the company’s share price has fallen by 48% per year, which means it is performing significantly worse than earnings. Announcement • Mar 28
Fujian Aonong Biological Technology Group Incorporation Limited to Report Q1, 2025 Results on Apr 30, 2025 Fujian Aonong Biological Technology Group Incorporation Limited announced that they will report Q1, 2025 results on Apr 30, 2025 New Risk • Jan 31
New major risk - Shareholder dilution The company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 199% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Negative equity (-CN¥1.4b). Earnings have declined by 59% per year over the past 5 years. Shareholders have been substantially diluted in the past year (199% increase in shares outstanding). Announcement • Dec 27
Fujian Aonong Biological Technology Group Incorporation Limited to Report Fiscal Year 2024 Results on Apr 30, 2025 Fujian Aonong Biological Technology Group Incorporation Limited announced that they will report fiscal year 2024 results on Apr 30, 2025 New Risk • Nov 14
New major risk - Revenue and earnings growth Earnings have declined by 59% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Negative equity (-CN¥1.4b). Earnings have declined by 59% per year over the past 5 years. Reported Earnings • Oct 31
Third quarter 2024 earnings released: CN¥0.32 loss per share (vs CN¥0.56 loss in 3Q 2023) Third quarter 2024 results: CN¥0.32 loss per share (improved from CN¥0.56 loss in 3Q 2023). Revenue: CN¥2.27b (down 56% from 3Q 2023). Net loss: CN¥279.0m (loss narrowed 42% from 3Q 2023). Revenue is forecast to grow 54% p.a. on average during the next 2 years, compared to a 11% growth forecast for the Food industry in China. Over the last 3 years on average, earnings per share has fallen by 29% per year but the company’s share price has fallen by 35% per year, which means it is performing significantly worse than earnings. Announcement • Sep 30
Fujian Aonong Biological Technology Group Incorporation Limited to Report Q3, 2024 Results on Oct 31, 2024 Fujian Aonong Biological Technology Group Incorporation Limited announced that they will report Q3, 2024 results on Oct 31, 2024 Reported Earnings • Aug 31
Second quarter 2024 earnings released: CN¥0.28 loss per share (vs CN¥0.71 loss in 2Q 2023) Second quarter 2024 results: CN¥0.28 loss per share (improved from CN¥0.71 loss in 2Q 2023). Revenue: CN¥2.25b (down 57% from 2Q 2023). Net loss: CN¥248.0m (loss narrowed 61% from 2Q 2023). Revenue is forecast to grow 45% p.a. on average during the next 2 years, compared to a 11% growth forecast for the Food industry in China. Over the last 3 years on average, earnings per share has fallen by 41% per year but the company’s share price has only fallen by 24% per year, which means it has not declined as severely as earnings. Announcement • Jun 28
Fujian Aonong Biological Technology Group Incorporation Limited to Report First Half, 2024 Results on Aug 31, 2024 Fujian Aonong Biological Technology Group Incorporation Limited announced that they will report first half, 2024 results on Aug 31, 2024 Announcement • May 18
Fujian Aonong Biological Technology Group Incorporation Limited, Annual General Meeting, Jun 06, 2024 Fujian Aonong Biological Technology Group Incorporation Limited, Annual General Meeting, Jun 06, 2024, at 14:00 China Standard Time. Location: Zhangzhou Science and Technology Park, Intersection of Xingting Road and Baolian Road, Shiting Town, Xiangcheng District, Zhangzhou, Fujian China Board Change • May 02
Less than half of directors are independent There are 5 new directors who have joined the board in the last 3 years. Of these new board members, 3 were independent directors. The company's board is composed of: 3 independent directors. 6 non-independent directors. Independent Director Feng Liu was the last independent director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Announcement • Mar 29
Fujian Aonong Biological Technology Group Incorporation Limited to Report Q1, 2024 Results on Apr 30, 2024 Fujian Aonong Biological Technology Group Incorporation Limited announced that they will report Q1, 2024 results on Apr 30, 2024 New Risk • Feb 01
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 6.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company. Announcement • Dec 30
Fujian Aonong Biological Technology Group Incorporation Limited to Report Fiscal Year 2023 Results on Apr 30, 2024 Fujian Aonong Biological Technology Group Incorporation Limited announced that they will report fiscal year 2023 results on Apr 30, 2024 Reported Earnings • Nov 01
Third quarter 2023 earnings released: CN¥0.56 loss per share (vs CN¥0.12 profit in 3Q 2022) Third quarter 2023 results: CN¥0.56 loss per share (down from CN¥0.12 profit in 3Q 2022). Revenue: CN¥5.11b (down 22% from 3Q 2022). Net loss: CN¥480.6m (down CN¥584.6m from profit in 3Q 2022). Revenue is forecast to grow 19% p.a. on average during the next 3 years, compared to a 13% growth forecast for the Food industry in China. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 48 percentage points per year, which is a significant difference in performance. Reported Earnings • Sep 02
Second quarter 2023 earnings released: CN¥0.71 loss per share (vs CN¥0.42 loss in 2Q 2022) Second quarter 2023 results: CN¥0.71 loss per share (further deteriorated from CN¥0.42 loss in 2Q 2022). Revenue: CN¥5.25b (up 13% from 2Q 2022). Net loss: CN¥629.6m (loss widened 94% from 2Q 2022). Revenue is forecast to grow 16% p.a. on average during the next 3 years, compared to a 13% growth forecast for the Food industry in China. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 54 percentage points per year, which is a significant difference in performance. Reported Earnings • Apr 30
First quarter 2023 earnings released: CN¥0.21 loss per share (vs CN¥0.54 loss in 1Q 2022) First quarter 2023 results: CN¥0.21 loss per share (improved from CN¥0.54 loss in 1Q 2022). Revenue: CN¥4.82b (up 16% from 1Q 2022). Net loss: CN¥179.7m (loss narrowed 49% from 1Q 2022). Revenue is forecast to grow 25% p.a. on average during the next 2 years, compared to a 14% growth forecast for the Food industry in China. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 71 percentage points per year, which is a significant difference in performance. Board Change • Nov 16
Less than half of directors are independent No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 12 experienced directors. No highly experienced directors. 4 independent directors (6 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Reported Earnings • Oct 29
Third quarter 2022 earnings released: EPS: CN¥0.12 (vs CN¥0.50 loss in 3Q 2021) Third quarter 2022 results: EPS: CN¥0.12 (up from CN¥0.50 loss in 3Q 2021). Revenue: CN¥6.59b (up 29% from 3Q 2021). Net income: CN¥104.0m (up CN¥444.3m from 3Q 2021). Profit margin: 1.6% (up from net loss in 3Q 2021). The move to profitability was driven by higher revenue. Revenue is forecast to grow 23% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Food industry in China. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 97 percentage points per year, which is a significant difference in performance. Buying Opportunity • May 24
Now 20% undervalued after recent price drop Over the last 90 days, the stock is down 22%. The fair value is estimated to be CN¥18.35, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 47% over the last 3 years. Meanwhile, the company became loss making. Reported Earnings • May 02
First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind First quarter 2022 results: CN¥0.54 loss per share (down from CN¥0.25 profit in 1Q 2021). Revenue: CN¥4.16b (up 6.7% from 1Q 2021). Net loss: CN¥351.7m (down 317% from profit in 1Q 2021). Revenue exceeded analyst estimates by 4.6%. Earnings per share (EPS) missed analyst estimates by 44%. Over the next year, revenue is forecast to grow 48%, compared to a 20% growth forecast for the industry in China. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 89 percentage points per year, which is a significant difference in performance. Board Change • Apr 27
Less than half of directors are independent No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 12 experienced directors. No highly experienced directors. 3 independent directors (6 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Reported Earnings • Oct 31
Third quarter 2021 earnings released: CN¥0.50 loss per share (vs CN¥0.25 profit in 3Q 2020) The company reported a mediocre third quarter result with weaker earnings and weaker control over costs, although revenues improved. Third quarter 2021 results: Revenue: CN¥5.10b (up 57% from 3Q 2020). Net loss: CN¥340.3m (down 307% from profit in 3Q 2020). Over the last 3 years on average, earnings per share has increased by 24% per year but the company’s share price has only increased by 12% per year, which means it is significantly lagging earnings growth. Reported Earnings • Aug 31
Second quarter 2021 earnings released: CN¥0.54 loss per share (vs CN¥0.33 profit in 2Q 2020) The company reported a mediocre second quarter result with weaker earnings and weaker control over costs, although revenues improved. Second quarter 2021 results: Revenue: CN¥4.33b (up 85% from 2Q 2020). Net loss: CN¥324.6m (down 274% from profit in 2Q 2020). Over the last 3 years on average, earnings per share has increased by 78% per year but the company’s share price has fallen by 8% per year, which means it is significantly lagging earnings. Price Target Changed • May 19
Price target increased to CN¥29.16 Up from CN¥21.97, the current price target is provided by 1 analyst. New target price is 162% above last closing price of CN¥11.15. Stock is down 27% over the past year. Reported Earnings • May 02
First quarter 2021 earnings released: EPS CN¥0.25 (vs CN¥0.27 in 1Q 2020) The company reported a solid first quarter result with improved earnings and revenues, although profit margins were weaker. First quarter 2021 results: Revenue: CN¥3.89b (up 123% from 1Q 2020). Net income: CN¥162.0m (up 7.3% from 1Q 2020). Profit margin: 4.2% (down from 8.6% in 1Q 2020). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 91% per year but the company’s share price has fallen by 4% per year, which means it is significantly lagging earnings. Reported Earnings • Mar 25
Full year 2020 earnings released: EPS CN¥0.95 (vs CN¥0.054 in FY 2019) The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2020 results: Revenue: CN¥11.5b (up 99% from FY 2019). Net income: CN¥573.0m (up CN¥543.8m from FY 2019). Profit margin: 5.0% (up from 0.5% in FY 2019). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 82% per year but the company’s share price has remained flat, which means it is significantly lagging earnings. Valuation Update With 7 Day Price Move • Feb 22
Investor sentiment improved over the past week After last week's 18% share price gain to CN¥16.11, the stock is trading at a trailing P/E ratio of 18.1x, up from the previous P/E ratio of 15.4x. This compares to an average P/E of 37x in the Food industry in China. Total returns to shareholders over the past three years are 25%. Is New 90 Day High Low • Feb 19
New 90-day high: CN¥15.51 The company is up 13% from its price of CN¥13.69 on 20 November 2020. The Chinese market is up 9.0% over the last 90 days, indicating the company outperformed over that time. However, it underperformed the Food industry, which is up 19% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥6.31 per share. Valuation Update With 7 Day Price Move • Jan 05
Investor sentiment improved over the past week After last week's 20% share price gain to CN¥14.85, the stock is trading at a trailing P/E ratio of 16.7x, up from the previous P/E ratio of 13.9x. This compares to an average P/E of 40x in the Food industry in China. Total returns to shareholders over the past three years are 4.8%. Is New 90 Day High Low • Dec 29
New 90-day low: CN¥12.37 The company is down 16% from its price of CN¥14.68 on 30 September 2020. The Chinese market is up 5.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Food industry, which is up 5.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥7.02 per share. Is New 90 Day High Low • Nov 06
New 90-day low: CN¥13.15 The company is down 28% from its price of CN¥18.21 on 07 August 2020. The Chinese market is down 1.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Food industry, which is down 7.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥6.05 per share. Is New 90 Day High Low • Oct 31
New 90-day low: CN¥13.54 The company is down 26% from its price of CN¥18.20 on 31 July 2020. The Chinese market is down 3.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Food industry, which is down 7.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥4.37 per share. Announcement • Oct 29
Fujian Aonong Biological Technology Group Incorporation Limited to Report Q3, 2020 Results on Oct 31, 2020 Fujian Aonong Biological Technology Group Incorporation Limited announced that they will report Q3, 2020 results on Oct 31, 2020 Is New 90 Day High Low • Oct 23
New 90-day low: CN¥13.63 The company is down 23% from its price of CN¥17.68 on 24 July 2020. The Chinese market is up 4.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Food industry, which is up 3.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥4.37 per share. Announcement • Sep 19
Liu Xueke, Su Guoyang, Wu Boyuan, and Liu Lianlong agreed to acquire 21% stake in Xiamen Aomu Trade Co., Ltd from Fujian Aonong Biological Technology Group Incorporation Limited (SHSE:603363) for CNY 0. Liu Xueke, Su Guoyang, Wu Boyuan, and Liu Lianlong agreed to acquire 21% stake in Xiamen Aomu Trade Co., Ltd from Fujian Aonong Biological Technology Group Incorporation Limited (SHSE:603363) for CNY 0 on January 12, 2018. Liu Xueke, Su Guoyang, Wu Boyuan, and Liu Lianlong will acquire 12% stake, 3% stake, 3% stake and 3% stake respectively. The transaction is subject to the Fujian Aonong Biological Technology shareholders’ approval. The transaction is approved by the Board of Fujian Aonong Biological Technology on January 12, 2018. Announcement • Aug 26
Fujian Aonong Biological Technology Group Incorporation Limited (SHSE:603363) completed the acquisition of the remaining 70% stake in Xiamen Yinxiang Meat Industry Co., Ltd. from Xiamen Yinxiang Group Co., Ltd. Fujian Aonong Biological Technology Group Incorporation Limited (SHSE:603363) entered into a letter of intent to acquire the remaining 70% stake in Xiamen Yinxiang Meat Industry Co., Ltd. from Xiamen Yinxiang Group Co., Ltd. for approximately CNY 250 million on June 10, 2020. The consideration of CNY 110 million will be payable within 7 working days from the date of signing of the agreement as advance payment. The consideration of CNY 70 million will be payable within three working days from the completion of the materials, after the entry into force of this agreement and the parties have made preliminary preparations for the cancellation of the original equity pledge and this industrial and commercial change. The consideration of CNY 16 million will be payable within 5 working days after completion of the corresponding industrial and commercial change procedures. The consideration of CNY 10 million will be payable within 5 working days after the issuance of audit report in 2020. The consideration of CNY 20 million will be payable within 5 working days after the issuance of audit report in 2021. The consideration of CNY 19.7 million will be payable within 5 working days after the issuance of audit report in 2022. As of the end of the performance commitment period of this agreement or the date of the final cash payment increase in valuation (whichever is later), the state key laboratory support unit has not been changed from Xiamen Yinxiang Group Co., Ltd. to the parties if the actual relying party is determined through negotiation, Xiamen Yinxiang Group Co., Ltd. shall return the equity transfer amount of CNY 15 million to Fujian Aonong Biological Technology Group Incorporation Limited within 5 working days and if the above changes have been completed, Fujian Aonong Biological Technology Group Incorporation Limited will return CNY 15 million to Xiamen Yinxiang Group Co., Ltd. within 5 working days.
After completion, Xiamen Yinxiang Meat Industry will be a wholly owned subsidiary of Fujian Aonong Biological Technology Group. As on April 30, 2020 Xiamen Yinxiang Meat Industry Co., Ltd reported total assets of CNY 90.74 million, net liabilities of CNY 12.71 million, revenues of CNY 68.23 million and net profit of CNY 1.59 million. The transaction is subject to Fujian Aonong Biological Technology's shareholder approval and approval of State Administration of Market Supervision and Administration. As of June 29, 2020, shareholders of Fujian Aonong Biological Technology approved the transaction in fourth extraordinary general meeting of 2020.
Fujian Aonong Biological Technology Group Incorporation Limited (SHSE:603363) completed the acquisition of the remaining 70% stake in Xiamen Yinxiang Meat Industry Co., Ltd. from Xiamen Yinxiang Group Co., Ltd. on August 26, 2020. The transaction has obtained the "Concentration of Undertakings Anti-monopoly Review No Further Review Decision" issued by the State Administration for Market Regulation. Announcement • Jul 08
Fujian Aonong Biological Technology Group Incorporation Limited to Report First Half, 2020 Results on Aug 20, 2020 Fujian Aonong Biological Technology Group Incorporation Limited announced that they will report first half, 2020 results on Aug 20, 2020 Announcement • Jun 19
Fujian Aonong Biological Technology Group Incorporation Limited (SHSE:603363) agreed to acquire 51% stake in Fu Jian Yangbao Biology Co., Ltd. for approximately CNY 180 million. Fujian Aonong Biological Technology Group Incorporation Limited (SHSE:603363) agreed to acquire 51% stake in Fu Jian Yangbao Biology Co., Ltd. for approximately CNY 180 million on June 19, 2020. Fu Jian Yangbao Biology revenue of CNY 0, total assets of CNY 184.3 million, net assets of CNY 172.3 million and net loss of CNY 1.8 million for the year ending, December 2019. 
